DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

@article{Yang2006DNAMC,
  title={DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.},
  author={Allen S. Yang and Ketan D Doshi and Sang-Woon Choi and Joel B. Mason and Rajan K Mannari and Vazganush Gharybian and Ren{\'e} Santos Luna and Asif Rashid and Lanlan Shen and Marcos R. H. Estecio and Hagop M Kantarjian and Guillermo Garcia-Manero and Jean-Pierre Issa},
  journal={Cancer research},
  year={2006},
  volume={66 10},
  pages={5495-503}
}
5-Aza-2'-deoxycytidine (decitabine) is postulated to have clinical activity in myeloid leukemias via its ability to inhibit DNA methylation. To study this, we examined DNA methylation in patients with leukemia treated with decitabine. Five days after the treatment, total genomic 5-methylcytosine/cytosine decreased on average by 14% (from 4.3% to 3.7%), whereas methylation of repetitive DNA elements showed a mean decrease of 9% and 16% for Alu and long interspersed nucleotide elements… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…